Skip to main content

LIVE

BBLG

Bone Biologics Corporation

BBLG

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1M

$0.62

-0.03%

P/E

Mkt Cap

$1.1M

52-Wk Range

$0.58–$4.13

52-Week Range

$0.58 - $4.13

P/E

Fwd P/E

Beta

0.53

Div Yield

0.00%

Avg Vol

48.4K

Shares Out

1.8M

Mkt Cap

$1.1M

Price action

Price chart

Down 71.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary NELL-1 recombinant protein technology with UCLA licensing exclusivity
  • Target-specific bone regeneration control versus traditional bone graft alternatives
  • Multi-specialty platform applicability across surgical disciplines
  • Established clinical foundation and intellectual property portfolio in regenerative medicine

Bear Case

1 risk

  • Low volatility (beta 0.5).

Growth

Stable outlook

Rising prevalence of degenerative disc disease and increasing spinal fusion procedure volume

Value

Valuation data unavailable

Momentum

Falling

-53.4% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 13, 2026

Q3 26 RECAP

AUG 14, 2026

Reported EPS of -$0.43 vs -$0.39 consensus (-10.3% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-10.3%

Revenue trend · last 8Q

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

vs Industry

How BBLG stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.